Loading clinical trials...
Loading clinical trials...
A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV46017
Conditions
Interventions
TV46017
Placebo
Locations
7
United States
Teva Investigational Site 13033
St Louis, Missouri, United States
Teva Investigational Site 13034
Raleigh, North Carolina, United States
Teva Investigational Site 78984
Adelaide, Australia
Teva Investigational Site 78985
Nedlands, Australia
Teva Investigational Site 79037
Auckland, New Zealand
Teva Investigational Site 79036
Hamilton, New Zealand
Start Date
March 1, 2015
Primary Completion Date
August 1, 2015
Completion Date
August 1, 2015
Last Updated
November 9, 2021
NCT07307781
NCT07509606
NCT07451977
NCT07082738
NCT07477600
NCT07382258
Lead Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions